

November 20, 2018



SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

JERSEY CITY, N.J., Nov. 20, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor conferences:

- The 30th Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace Hotel on Tuesday, November 27, 2018 at 10:10 a.m. ET.
- The Evercore ISI HealthConX Conference at the Boston Harbor Hotel on Wednesday, November 28, 2018 at 11:45 a.m. ET.

Live webcasts of the presentations will be available on the Investors section of the Company's website: www.scynexis.com. Replays of the presentations will be available approximately two hours after each event and will be available for two weeks following each presentation.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by *Candida* and *Aspergillus* species. For more information, visit www.scynexis.com.

CONTACT:

Investor Relations

Natalie Wildenradt
Argot Partners
Tel: 212-600-1902
natalie@argotpartners.com

Media Relations

George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093
george@macbiocom.com

View original content: <http://www.prnewswire.com/news-releases/scynexis-inc-to-present->

[at-upcoming-investor-conferences-300753206.html](https://www.scynexis.com/press-releases/2020/04/2020-04-20-at-upcoming-investor-conferences-300753206.html)

SOURCE SCYNEXIS, Inc.